ROS1 and non-small cell lung carcinoma: This conclusion not only provides partial insight into the patient’s resistance to pembrolizumab in the context of newly emerged ROS1 rearrangement but also supports that there was no initial missed diagnosis of ROS1, as NSCLC with ROS1 rearrangement shows a poor response to ICIs.